Menu
Microsoft strongly encourages users to switch to a different browser than Internet Explorer as it no longer meets modern web and security standards. Therefore we cannot guarantee that our site fully works in Internet Explorer. You can use Chrome or Firefox instead.

Better Buy: Johnson & Johnson vs. Pfizer


Better Buy: Johnson & Johnson vs. Pfizer

They're two of the oldest, largest, and most respected healthcare companies around. But one has made investors much happier than the other in recent years. Johnson & Johnson (NYSE: JNJ) stock is up more than twice as much as Pfizer (NYSE: PFE) stock over the past five years, and it's a similar story so far in 2017.

That's looking in the rearview mirror, though. Which of these healthcare stocks is the better choice for long-term investors now? Here's how Johnson & Johnson and Pfizer compare.

Image source:Getty Images.

Continue reading


Source: Fool.com

Johnson & Johnson Stock

€136.76
0.280%
Johnson & Johnson gained 0.280% compared to yesterday.
The stock is one of the favorites of our community with 33 Buy predictions and 1 Sell predictions.
With a target price of 195 € there is a positive potential of 42.59% for Johnson & Johnson compared to the current price of 136.76 €.
Like: 0
JNJ
Share

Comments